) second-quarter adjusted loss per share of 70 cents was narrower
than the Zacks Consensus Estimate of a loss of 69 cents but wider
than the year-ago loss of 64 cents per share. The wider
year-over-year loss was due to higher expenses.
InterMune reported revenues of $14.4 million in the second
quarter of 2013, compared with year-ago revenues of $5.5 million.
Revenues also increased 37% on a sequential basis.
The sharp increase in total revenues was primarily due to a
boost in Esbriet (pirfenidone) sales. The drug was launched in
Germany in Sep 2011. Revenues were above the Zacks Consensus
Estimate of $13 million.
Esbriet was the sole contributor to InterMune's total revenues in
the second quarter of 2013. Esbriet is approved for the treatment
of idiopathic pulmonary fibrosis (IPF), a fatal lung disease.
During the quarter, research and development (R&D) expenses
increased 9.4% to $27.5 million. The increase in R&D was due
to expenses associated with the ASCEND trial.
The ASCEND trial will support the filing of Esbriet for the
treatment of IPF in the US. In Jan 2013, the company completed
enrollment for the phase III study in the US. InterMune confirmed
in its press release that the results from the ASCEND trial are
expected in the second quarter of 2014.
Selling general and administrative (SG&A) expenses were up
45.4% to $37.3 million during the reported quarter. The increase
in SG&A expenses during the reported quarter was primarily
attributable to expenses related to the launch and pre-launch of
Esbriet in the EU and Canada.
Apart from announcing its results, the company also updated its
previously announced guidance for the year 2013. InterMune now
expects Esbriet sales in the range of $55−$70 million (previous:
$40−$70 million) in 2013. Total revenues for 2013 as per the
Zacks Consensus Estimate are $59 million.
The company, however, maintained its 2013 operating expenses
guidance at $245-$285 million. InterMune still expects 2013
R&D expenses in the range of $100-$120 million and SG&A
expenses in the range of $145-$165 million.
To date, Esbriet is successfully priced and reimbursed in 13
European countries, namely, Austria, Belgium, Denmark, France,
Germany, Iceland, Luxembourg, Norway, Sweden, Finland, Italy,
England and Ireland. InterMune launched the drug in Italy earlier
this month and expects to launch it in England and Wales by next
Moreover, the company expects to provide an update on pricing and
reimbursement discussions in Spain and the Netherlands by the end
of the year.
Though Esbriet is the only approved medicine for IPF, companies
) are developing therapies to treat IPF. We remain concerned
about the fact that InterMune is dependent on a single product
for growth. Meanwhile, we expect investor focus to remain on the
pricing and reimbursement in the remaining EU countries.
InterMune, a biotechnology company, carries a Zacks Rank #3
(Hold). Other biotech stocks such as
WuXi PharmaTech (Cayman) Inc.
) currently look better positioned carrying a Zacks Rank #1
INTERMUNE INC (ITMN): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
WUXI PHARMATECH (WX): Free Stock Analysis
To read this article on Zacks.com click here.